Evommune (NYSE:EVMN) Upgraded at Clear Str

Clear Str upgraded shares of Evommune (NYSE:EVMN) to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

EVMN has been the topic of a number of other research reports. Morgan Stanley reaffirmed an “overweight” rating and set a $54.00 price objective on shares of Evommune in a report on Wednesday, February 18th. Weiss Ratings began coverage on shares of Evommune in a research note on Tuesday, February 3rd. They set a “sell (e)” rating on the stock. Raymond James Financial initiated coverage on shares of Evommune in a research note on Wednesday, January 7th. They issued a “strong-buy” rating and a $40.00 price objective for the company. Wall Street Zen raised shares of Evommune from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. Finally, Leerink Partners began coverage on Evommune in a report on Monday, December 1st. They issued an “outperform” rating and a $42.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $47.17.

Evommune Trading Down 1.4%

NYSE:EVMN opened at $23.75 on Tuesday. The stock has a market capitalization of $855.43 million and a price-to-earnings ratio of -2.94. Evommune has a 1-year low of $13.89 and a 1-year high of $33.20. The business has a 50-day simple moving average of $23.26.

Evommune (NYSE:EVMN) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.61).

Institutional Trading of Evommune

A number of hedge funds have recently made changes to their positions in EVMN. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Evommune during the 4th quarter valued at approximately $34,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Evommune during the fourth quarter worth $179,000. XTX Topco Ltd acquired a new position in shares of Evommune in the 4th quarter valued at about $321,000. Oxford Asset Management LLP bought a new stake in shares of Evommune during the 4th quarter valued at about $335,000. Finally, State Street Corp bought a new stake in shares of Evommune during the 4th quarter valued at about $539,000.

Key Stories Impacting Evommune

Here are the key news stories impacting Evommune this week:

• Positive Sentiment: Clear Street initiated coverage with a Buy recommendation, giving independent buying interest and analyst coverage that can support demand for the shares. Clear Street initiates coverage of Evommune (EVMN) with buy recommendation
• Positive Sentiment: Evommune’s Relative Strength (RS) rating rose to 91, indicating stronger price momentum versus peers — a technical positive that can attract momentum-focused buyers. Stocks to watch: Evommune sees RS rating rise to 91
• Neutral Sentiment: HC Wainwright lowered its price target from $65 to $50 but maintained a “Buy” rating — the cut reduces upside vs. prior targets but still implies substantial upside from current levels, leaving investor reaction mixed. Benzinga coverage of HC Wainwright price target change
• Negative Sentiment: HC Wainwright materially reduced near‑term and full‑year EPS forecasts: Q1 2026 to ($0.83), Q2 to ($0.71), Q3 to ($0.71), Q4 to ($0.75) and FY2026 to ($3.00) (down from prior estimates). The shop also issued a FY2027 EPS forecast of ($3.30). Those downgrades signal worsening profitability/visibility and are the primary driver of today’s weakness. HC Wainwright Issues Pessimistic Forecast for Evommune (NYSE:EVMN) Stock Price

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.